Underlying Mechanisms and Therapeutic Strategies for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ).

Author: EndoYasuo, KumamotoHiroyuki, NakamuraMasanori, SasakiKeiichi, SugawaraShunji, TakahashiTetsu, Takano-YamamotoTeruko

Paper Details 
Original Abstract of the Article :
Bisphosphonates (BPs), with a non-hydrolysable P-C-P structure, are cytotoxic analogues of pyrophosphate, bind strongly to bone, are taken into osteoclasts during bone-resorption and exhibit long-acting anti-bone-resorptive effects. Among the BPs, nitrogen-containing BPs (N-BPs) have far stronger an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1248/bpb.b16-01020

データ提供:米国国立医学図書館(NLM)

Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ): Unraveling the Mechanisms and Seeking Solutions

Bisphosphonates (BPs), widely used to treat osteoporosis and other bone diseases, have been associated with a serious side effect known as bisphosphonate-related osteonecrosis of the jaw (BRONJ). This review, published in the journal Journal of Bone and Mineral Metabolism, delves into the complex mechanisms underlying BRONJ, aiming to shed light on this debilitating condition and identify potential therapeutic strategies. The authors conducted a series of experiments in mice to investigate the effects of different BPs on bone and soft tissues.

The Delicate Balance of Bone Health

The authors' research revealed that nitrogen-containing BPs (N-BPs), which have stronger anti-bone-resorptive effects than non-N-BPs, can directly induce inflammation and necrosis in soft tissues. They also found that these effects are exacerbated by the presence of lipopolysaccharide, a bacterial cell wall component. The study suggests that N-BPs are transported into cells via phosphate transporters, and that non-N-BPs, such as etidronate and clodronate, can inhibit this transportation and potentially reduce or prevent N-BP-induced inflammation and necrosis.

Navigating the Treatment Landscape

The authors propose that phosphate-transporter-mediated and inflammation/infection-promoted mechanisms play a key role in the development of BRONJ. They recommend etidronate as a potential substitute drug for N-BPs and clodronate as a combination drug with N-BPs. Their clinical trials support the role of etidronate in treating BRONJ. While BRONJ remains a complex and challenging condition, this research offers valuable insights into its underlying mechanisms and potential therapeutic approaches.

Dr.Camel's Conclusion

The desert landscape of bone health can be treacherous, and BPs, while offering benefits, can also have unforeseen consequences. This review sheds light on the complex mechanisms behind BRONJ, highlighting the importance of careful consideration of the risks and benefits of BPs. The authors' research offers hope for finding new ways to treat and prevent this debilitating condition, reminding us that even in the most arid of terrains, solutions can be found.

Date :
  1. Date Completed 2018-03-06
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

28566618

DOI: Digital Object Identifier

10.1248/bpb.b16-01020

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.